Alnylam: The Best Hepatitis B Play?

Alnylam (ALNY) has big plans for hepatitis B treatment, but Gilead's (GILD) program is far closer to market.

May 14, 2014 at 6:30PM

Alnylam (NASDAQ:ALNY) shares jumped this week after reporting that it would actively advance an RNAi program for the treatment of chronic hepatitis B.

Up to 400 million people suffer from chronic hepatitis B worldwide and, currently, there's no cure. The sheer size of the patient population and the significant need for better treatment options have caught the attention of drug developers eager to address this important market.

However, Alnylam's new program could be years from commercialization, suggesting investors may be better served focusing on late-stage programs under development at Gilead (NASDAQ:GILD) instead.

ALNY Chart

ALNY data by YCharts

First, a bit of background
Two of the most commonly used treatments for hepatitis B are Bristol-Myers' Baraclude and Gilead's Viread. Both are used to reduce the virus' presence in patients, and to curb the virus' ability to replicate.

Baraclude, which won FDA approval in 2005, has been used in more than 400,000 patients since its launch, and racked up more than $1.5 billion in sales last year for Bristol, up 10% from 2012. Baraclude's sales momentum continued into the first quarter, with Bristol reporting sales of the drug rising 11% year over year, to $406 million.

Viread, which is approved for use in HIV and hepatitis B patients, is also a top seller. Viread's sales totaled $950 million in 2013, up 13% from 2012, and reached $210 million in the first quarter.

However, despite Baraclude and Viread's commercial success, there remains significant room for improvement. Roughly 600,000 people still die from the effects of chronic hepatitis B due to liver failure or liver cancer each year. Most of those deaths occur in developing markets, including Africa and East Asia, where the disease is most prevalent and vaccines are less common; however, the disease is found everywhere. For example, up to 1% of Europeans and Americans are chronically infected with the disease.

Promising new treatments
Given the significant need for new therapies, it's understandable that investors got excited about Alnylam's plans to advance ALN-HBV, a drug that was acquired when Alnylam purchased Merck's RNAi assets in January. However, before investors get too far ahead of themselves, it's important to remember that ALN-HBV is a pre-clinical drug.

Alnylam hasn't filed an IND for ALN-HBV yet (the first step in taking a drug from the lab to human patients), and doesn't think it will file it until late next year. Once the drug moves into human trials, there's also no guarantee that it will make it to market. Roughly 90% of drugs in phase 1 trials fail to make it to the FDA for approval, with the majority -- some 60% -- failing during phase 2. And even if the drug makes it through phase 3 and gets in front of the FDA, there's no guarantee the agency will approve it.

Dynavax successfully demonstrated that its hepatitis B vaccine, Heplisav, outperformed GlaxoSmithKline's hepatitis B vaccine Engerix-B during trials; however, both the FDA and European regulators nixed approval over concerns tied to the study's ability to detect rare, but serious, side effects. As a result, Dynavax has been forced to begin another costly phase 3 trial to quell concerns, data for which isn't expected until late in 2015.

Closer to realization
Since Alnylam's potential hepatitis B treatment is years away, investors may want to concentrate on compounds closer to market, including Gilead's tenofovir alafenamide, a drug being studied as a treatment for both HIV and hepatitis B.

Tenofovir alafenamide is a novel formulation of Gilead's Viread, and the new tenofovir formulation showed similar efficacy to Viread in phase 1b trials with fewer side effects -- particularly relating to kidney function. Gilead has since advanced the drug into phase 3, with an estimated primary completion date of November 2015.

Beyond tenofovir alafenamide, Gilead is also working on GS-4774 and GS-9620, which are in phase 2 and phase 1 trials, respectively. Data from the GS-4774's phase 2 trial should be reported in six to 12 months.

Fool-worthy final thoughts
There's no question that hepatitis B is a significant disease that requires new, innovative therapies. Alnylam's ALN-HBV program could prove wildly successful, or it may end up on the cutting room floor. It's just too early to know for sure. That risk suggests that investors should keep an eye on Alnylam's program, but may find that Gilead's hepatitis B program makes for a better investment, particularly in light of Gilead's proven success in treating hepatitis B, HIV, and hepatitis C. 

Alnylam is years away from realizing its potential, but this stock may be realizing its potential today
Give me five minutes, and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer handpicks one stock with outstanding potential. But it's not just any run-of-the-mill company; it’s a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% during the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.The Motley Fool recommends Alnylam Pharmaceuticals and Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers